✦ LIBER ✦

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

✍ Scribed by Ravi Vij; Noemi Horvath; Andrew Spencer; Kerry Taylor; Saroj Vadhan-Raj; Robert Vescio; Judy Smith; Yi Qian; Howard Yeh; Susie Jun

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 187 KB
Volume: 84
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.21509

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I safety study of enzastaurin pl

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. P 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB 👁 2 views

The addition of interferon or high dose

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486

✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera

A one-year, phase I/IIa, open-label pilo

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis–associated active interstitial lung disease

✍ Dinesh Khanna; Rajeev Saggar; Maureen D. Mayes; Fereidoun Abtin; Philip J. Cleme 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB 👁 2 views

Prognostic significance of the S-phase f

Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on eastern cooperative oncology group treatment trial E9486

✍ Trendle, M.C.; Leong, T.; Kyle, R.A.; Katzmann, J.A.; Oken, M.M.; Kay, N.E.; Van 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB 👁 2 views

The bone marrow plasma cell labeling index (PCLI) as measured by bromodeoxyuridine uptake is a well-established independent prognostic factor for patients with newly diagnosed multiple myeloma, but the test is not easily done in most laboratories. The purpose of this study was to determine if the pr